Classification of scientific publications is of great importance in biomedical research evaluation. However, accurate classification of research publications is challenging and normally is performed in a rather subjective way. In the present paper, we propose to classify biomedical publications into superfamilies, by analysing their citation profiles, i.e. the location of citations in the structure of citing articles. Such a classification may help authors to find the appropriate biomedical journal for publication, may make journal comparisons more rational, and may even help planners to better track the consequences of their policies on biomedical research.
There are many algorithms that help us understand how genome-scale metabolic networks work and what are their capabilities. But unfortunately, the majority of these methods are based on integer linear programming suffer from long run times and high instrumental demand. Optimal solutions in any constraint-based modeling as genome-scale metabolic networks models are on the extreme points of the solution space. We introduce a fast and simple toolbox that reveals extreme characters of metabolic networks in desired situations which can unmask the hidden potentials of metabolic networks. Determining the possibility of coupling between two desired reaction and the capability of synergic substrate consuming are examples of the applications of this method. Fast enumeration of elementary flux modes that exist in extreme points of phase plane of any two reactions is another achievement of this study.
At the forefront of biopharmaceutical industry, the messenger RNA (mRNA) technology offers a flexible and scalable platform to address the urgent need for world-wide immunization in pandemic situations. This strategic powerful platform has recently been used to immunize millions of people proving both of safety and highest level of clinical efficacy against infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here we provide preclinical report of COReNAPCIN ® ; a vaccine candidate against SARS-CoV-2 infection. COReNAPCIN ® is a nucleoside modified mRNA-based vaccine formulated in lipid nanoparticles (LNPs) for encoding the full-length prefusion stabilized SARS-CoV-2 spike glycoprotein on the cell surface. Vaccination of C57BL/6 and BALB/c mice and rhesus macaque with COReNAPCIN ® induced strong humoral responses with high titers of virus-binding and neutralizing antibodies. Upon vaccination, a robust SARS-CoV-2 specific cellular immunity was also observed in both mice and non-human primate models. Additionally, vaccination protected rhesus macaques from symptomatic SARS-CoV-2 infection and pathological damage to the lung upon challenging the animals with high viral loads of up to 2×10 8 live viral particles. Overall, our data provide supporting evidence for COReNAPCIN ® as a potent vaccine candidate against SARS-CoV-2 infection for clinical studies.